Systemic gene therapy for arthritis

Drugs of Today

Volumn 35, Issue 4-5, 1999, Pages 361-377

  Chernajovsky, Yuti ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; COLLAGEN TYPE 2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL MODEL; ARTHRITIS; CONFERENCE PAPER; GENE THERAPY; MOUSE; NONHUMAN; T LYMPHOCYTE; TARGET CELL;

EID: 0032787935     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.4-5.552210     Document Type: Conference Paper

References (99)

1. Feldmann, M., Brennan, F.M., Maini, R.N. Rheumatoid arthritis. Cell 1996, 85: 307-10.
2. Williams, W.M., Ehrenstein, M.R., Isenberg, D.A. The background to autoimmunity. In: Immunopharmacology of Joints and Connective Tissue. M.E. Davies and J.T. Dingle (Eds.). Academic Press: London 1994, 1-34.
3. Wordsworth, B.P., Lanchbury, J.S.S., Sakkas, L.I., Welsh, K.I., Panayi, Y.I., Bell, J.I. HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the the HLA class II region. Proc Natl Acad Sci USA 1989, 86: 10049-53.
4. Wordsworth, P., Pile, K. Etiology. In: Rheumatology. J.H. Klippel and P.A. Dieppe (Eds.). Mosby: St. Louis 1994, 8.1-10.
5. Matteson, E.L., Cohen, M.D., Conn, D.L. Clinical features-systemic involvement. In: Rheumatology. J.H. Klippel and P.A. Dieppe (Eds.). Mosby: St. Louis 1994, 5.1-8.
6. Feldmann, M., Elliot, M.J., Woody, J.N., Maini, R.N. Anti-tumor necrosis a therapy in rheumatoid arthritis. Adv Immunol 1997, 64: 283-350.
7. Brennan, F.M., Chantry, D., Jackson, A., Maini, R., Feldmann, M. Inhibitory effect of TNF antibodies on synovial cell IL-1 production in rheumatoid arthritis. Lancet 1989, ii: 244.
8. Feldmann, M., Brennan, F.M., Maini, R.N. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996, 14: 397-440.
9. Keffer, J., Probert, L., Cazlaris, H. et al. Transgenic mice expressing human TNF: A predictive genetic model of arthritis. EMBO J 1991, 10: 4025-31.
10. Williams, R.O., Feldmann, M., Maini, R.N. Anti TNF ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992, 89: 9784-8.
11. Williams, R.O., Mason, L.J., Feldmann, M., Maini, R.N. Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994, 91: 2762-6.
12. Elliott, M., Maini, R.N., Feldmann, M. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF α. Arthritis Rheum 1993, 36: 1681-9.
13. Elliott, M.J., Maini, R.N., Feldmann, M. et al. Randomised double-blind comparison of a chimaeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344: 1105-10.
14. Williams, R.O., Ghrayeb, J., Feldmann, M., Maini, R.N. Successful therapy of collagen induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 1995, 84: 433-9.
15. Moreland, L.W., Margolies, G., Heck, L.W. Jr. et al. Recombinant soluble TNF-R (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996, 23: 1849-55.
16. Chernajovsky, Y., Adams, G., Podhajcer, O., Mueller, G., Robbins, P., Feldmann, M. Inhibition of transfer of collagen-induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble human TNF receptor. Gene Ther 1995, 2: 731-5.
17. Neve, R., Kissonerghis, M., Feldmann, M., Chernajovsky, Y. Expression of an efficient small molecular weight TNF/lymphotoxin antagonist. Cytokine 1996, 8: 365-70.
18. Dranoff, G., Jaffee, E., Lazenby, A. et al. Vaccination with irradiated tumor cells engineered to secrete murine GMCSF stimulates potent, specific, and long lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993, 90: 3539-43.
19. Chernajovsky, Y., Adams, G., Triantaphyllopoulos, K., Leddam, M.F., Podhajcer, O.L. Pathogenic lymphoid cells engineered to express TGF-β1 ameliorate disease in a collagen-induced arthritis model. Gene Ther 1997, 4: 553-9.
20. Peppel, K., Crawford, D., Beutler, B. A TNF receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991, 174: 1483-9.
21. Triantaphyllopoulos, K., Neve, R., Adams, G. et al. Expression of cytokines and cytokine inhibitors in retroviral vectors for use in gene therapy of chronic relapsing experimental allergic encephalomyelitis. Mult Scler 1996, 2: 23.
22. Chernajovsky, Y., Annenkov, A., Dreja, H. A novel truncated form of human soluble complement receptor 1 delivered by gene therapy prevents and ameliorates collagen-induced arthritis by inhibiting B-and T-cell responses. (submitted) 1997.
23. Annenkov, A., Moyes, S., Eshhar, Z., Mageed, R., Chernajovsky, Y. Redirecting lymphocytes to type Il collagen using single chain Fv/g fusion receptor, (submitted) 1997.
24. b-tsA58 transgenic mouse. Proc Natl Acad Sci USA 1991, 88: 5096-100.
25. Almazan, G., McKay, R. An oligodendrocyte precursor cell line from rat optic nerve. Brain Res 1992, 579: 234-45.
26. Markowitz, D., Goff, S., Bank, A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988, 167: 400-6.
27. Pear, W.S., Nolan, G.P., Scott, M.L., Baltimore, D. Production of high titer helper free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993, 90: 8392-6.
28. Williams, R.O., Plater-Zyberk, C., Williams, D.G., Maini, R.N. Successful transfer of collagen-iduced arthritis to SCID mice. Clin Exp Immunol 1992, 88: 455-60.
29. Butler, D., Scallon, B., Meager, A. et al. TNF receptor fusion proteins are effective inhibitors of TNF-mediated cytotoxicity on human KYM-1D4 rhabdomyosarcoma cells. Cytokine 1994, 6: 616-23.
30. Leeuwenberg, J.F.M., Jeunhomme, T.M.A.A., Buurman, W. Slow release of soluble TNF-R by monocytes in vitro. J Immunol 1994, 152: 4036-43.
31. Gray, P.W., Barrett, K., Chantry, D., Turner, M., Feldmann, M. Cloning of human TNF receptor cDNA and expression of recombinant soluble TNF-binding protein. Proc Natl Acad Sci USA 1990, 87: 7380-4.
32. Jacobs, C.A., Beckmann, M.P., Mohler, K., Maliszewski, C.R., Fanslow, W.C., Lynch, D.H. Pharmacokinetic parameters and biodistribution of soluble cytokine receptors. Intl Rev Exp Pathol 1993, 34B: 123-35.
33. Bemelmans, M.H.A., Gouma, D.J., Buurman W.A. Influence of nephrectomy on TNF receptor clearance in a murine model. J Immunol 1993, 150: 2007-17.
34. Barcellos-Hoff, M.H., Derynck, R., Tsang, M.L., Weatherbee, J.A. TGF-β activation in irradiated murine mammary gland. J Clin Invest 1994, 93: 892-9.
35. Roberts, A.B., Sporn, M.B. The transforming growth factor-βs. In: Peptide Growth Factors and their Receptors. M. Sporn and A. Roberts (Eds.). Springer-Verlag: New York 1990, 419-72.
36. Brennan, F.M., Chantry, D., Turner, M., Foxwell, B., Maini, R.N., Feldmann, M. Detection of TGF-β in rheumatoid arthritis synovial tissue: Lack of effect on spontaneous cytokine production in joint cell cultures. Clin Exp Immunol 1990, 81: 278-85.
37. Kuruvilla, A.P., Shah, R., Hochwald, G.M., Liggitt, H.D., Palladino M.A. Protective effect of TGF-β1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci USA 1991, 88: 2918-21.
38. Allen, J.B., Manthey, C.L., Hand, A.R., Ohura, K., Ellingstworth, L., Wahl, S.M. Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor β. J Exp Med 1990, 171: 231-47.
39. Brandes, M.E., Allen, J.B., Ogawa, Y., Wahl, S.M. TGF-β1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest 1991, 87: 1108-13.
40. Shull, M.M., Ormsby, I., Kier, A.B. et al. Targeted disruption of the mouse TGF-β1 gene results in multifocal inflammatory disease. Nature 1992, 359: 693-9.
41. Devajyothi, C., Kalvakolanu, I., Babcock, G.T., Vasavada, H.A., Howe, P.H., Ransohoff, R.M. Inhibition of IFN-γ-induced MHC class II gene transcrption by IFN-β and TGF-β1 in human astrocytoma cells. J Biol Chem 1993, 268: 18794-800.
42. Croxford, J.L., Baker, D., Triantaphyllopoulos, K., Feldmann, M., Chernajovsky, Y. Cytokine gene therapy in chronic relapsing experimental allergic encephalomyelitis. Mult Scler 1996, 2: 20.
43. Wang, Y., Rollins, S.A., Madri, J.A., Matis, L.A. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 1995, 92: 8955-9.
44. Wang, Y., Hu, Q., Madri, J.A., Rollins, S.A., Chodera, A., Matis, L.A. Amelioration of lupus-like autoimmune disease in NZB/W F1 mice after treatment with a blocking monoclonal antibody specific for complement component 5. Proc Natl Acad Sci USA 1996, 93: 8563-8.
45. Mori, L., Loetscher, H., Kakimoto, K., Bluethmann, H., Steinmetz, M. Expression of a transgenic T-cell receptor β chain enhances collagen-induced arthritis. J Exp Med 1992, 176: 381-8.
46. Lens, J.W., van der Bers, W.B., van de Putte, L.B., Berden, J.H., Lems, S.P. Flare-up of antigen induced arthritis in mice after challenge with intravenous antisera: Effects of pretreatment with cobra venom factor and anti-lymphocyte antiserum. Clin Exp Immunol 1984, 3: 520-8.
47. Stuart, J.M., Cremer, M.A., Townes, A.S., Kang, A.H. Type II collagen-induced arthritis in rats: Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J Exp Med 1982, 155: 1-16.
48. Kalli, K.R., Hsu, P., Fearon, D.T. Therapeutic uses of recombinant complement protein inhibitors. Springer Semin Immunopathol 1994, 15: 417-31.
49. Hourcade, D., Holers, V.M., Atkinson, J.P. The regulators of complement activation (PICA) gene cluster. Adv Immunol 1989, 45: 381-416.
50. Weisman, H.F., Bartow, T., Leppo, M.K. et al. Soluble human complement receptor 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990, 249: 146-51.
51. Pemberton, M., Anderson, G., Vetvicka, V., Justus, D.E., Ross, G.D. Microvascular effects of complement blockade with soluble rCR1 on ischemia/reperfusion injury of skeletal muscle. J Immunol 1993, 150: 5104-13.
52. Yeh, C.G., Marsh, H.C. Jr., Carson, G.R. et al. Recombinant soluble human CR1 inhibits inflammation in the reversed passive Arthus reaction in rats. J Immunol 1991, 146: 250-6.
53. Mulligan, M.S., Yeh, C.G., Rudolph, A.R., Ward, P.A. Protective effects of sCR1 in complement-and neutrophil-mediated tissue injury. J Immunol 1992, 148: 1479-85.
54. Piddlesden, S.J., Storch, M.K., Hibbs, M., Freeman, A.M., Lassman, H., Morgan, B.P. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol 1994, 152: 5477-84.
55. Pruitt, S.K., Baldwin, W.M.I., Marsh, H.C. Jr., Lin, S.S., Yeh, C.G., Bollinger, R.R. The effect of soluble CR1 on hyperacute xenograft rejection. Transplantation 1991, 52: 868-73.
56. Gross, G., Eshhar, Z. Endowing T-cells with antibody specificity using chimeric T-cell receptors. FASEB J 1992, 6: 3370-8.
57. Goverman, J., Gomez, S.M., Segesman, K.D., Hunkapiller, T., Laug, W.E., Hood, L. Chimeric immunoglobulin-T-cell receptor proteins form functional receptors: Implications for T-cell receptor complex formation and activation. Cell 1990, 60: 929-39.
58. Hwu, P., Shafer, G.E., Treisman, J. et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody varaible region and the Fc receptor γ chain. J Exp Med 1993, 178: 361-6.
59. Lustgarten, J., Eshhar, Z. Specific elimination of IgE production using T-cell lines expressing chimeric T-cell receptor genes. Eur J Immunol 1995, 25: 2985-91.
60. Weijtens, M.E.M., Willemsen, R.A., Valerio, D., Stam, K., Bolhuis, R.L.H. Single chain Ig/g gene-redirected human T-lymphocytes produce cytokines, specifically lyse tumor cels and recycle lytic capacity. J Immunol 1996, 157: 836-43.
61. Moritz, D., Wels, W., Mattem, J., Groner, B. Cytotoxic T-lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 1994, 91: 4318-22.
62. Hwu, P., Yannelli, J., Kriegler, M. et al. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with TNF-α cDNA for the gene therapy of cancer in humans. J Immunol 1993, 150: 4104-15.
63. Londei, M. Persistance of collagen type II specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci USA 1989, 86: 636-40.
64. Jasin, H.E. Autoantibody specificities of immune complexes sequestered in articular cartilage of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1985, 28: 241-8.
65. Gross, G., Waks, T., Eshhar, Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody type specificity. Proc Natl Acad Sci USA 1989, 86: 10024-8.
66. Gross, G., Waks, T., Eshhar, Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody type specificity. Proc Natl Acad Sci USA 1989, 86: 10024-8.
67. Gross, J.A., St. John, T., Allison, J.P. The murine homologue of the T-lymphocyte antigen CD28: Molecular cloning and cell surface expression. J Immunol 1990 144: 3201-10.
68. Kuo, C.-L., Hood, L. Antigen/major histocompatibility complex-specific activation of murine T-cells transfected with functionally rearranged T-cell receptor genes. Proc Natl Acad Sci USA 1987, 84: 7614-8.
69. Vivier, E., Rochet, N., Ackerly, M., Levine, P.J.H., Daley, J., Anderson, P. Signalling function of reconstituted CD16:x:g receptor complex isoforms. Intl Immunol 1992, 4: 1313-23.
70. Holmdahl, R., Rubin, K., Klarreskog, L., Larsson, E., Wigzell, H. Characterization of the antibody response in mice with type II collagen-induced arthritis, using monoclonal anti-type II collagen antibodies. Arthritis Rheum 1986, 29: 400-10.
71. Mo, J.A., Scheynius, A., Nilsson, S., Holmdahl, R. Germline-encoded IgG antibodies bind mouse cartilage in vivo: Epitope-and idiotype-specific binding and inhibition. Scand J Immunol 1994, 39: 122-30.
72. Bessis, N., Boissier, M.C., Caput, D., Fradelizi, D., Fournier, C. Cytokine gene-therapy using il-4 and IL-13 in murine collagen-induced arthritis. Clinical Research 1994, 42: A135.
73. Erb, K.J., Rüger, B., von Brevern, M., Ryffel, B., Schimpl, A., Rivett, K. Constitutive expression of IL-4 in vivo causes autoimmune-type disorders in mice. J Exp Med 1997, 185: 329-39.
74. Bandara, G., Mueller, G.M., Galea-Lauri, J. et al. Intraarticular expression of biologically active IL-1 receptor antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci USA 1993, 90: 10764-8.
75. Ghivizzani, S.C., Kang, R., Hatton, C. et al. In vivo delivery of genes encoding soluble receptors for il-1 and TNF-α results in a synergistic therapeutic effect in antigen-induced arthritis in the rabbit knee. Arthritis Rheum 1996, 39: 1680.
76. Christenson, L., Dionne, K.E., Lysaght, M.J Biomedical applications of immobilized cells In: Fundamentals of Animal Cell Encapsulation and Immobilization. M.F.A. Goosen (Ed.). CRC Press: New York 1993, 7-41.
77. Aebischer, P., Schluep, M., Déglon, N. et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotropic lateral sclerosis patients. Nat Med 1996, 2: 696-9.
78. Sany, J. New immunological treatments for rheumatoid arthritis. Rev Rheum 1993, 60: 197-205.
79. Chernajovsky, Y., Feldmann, M., Maini, R.N. Gene therapy of rheumatoid arthritis via cytokine regulation: Future perspectives. Br Med Bull 1995, 51: 503-16.
80. Bach, J.-F. Immunosuppresive therapy of autoimmune diseases. Immunol Today 1993, 14: 322-6.
81. Kramer, R., Zhang, Y., Gehrmann, J., Gold, R., Thoenen, H., Wekerle, H. Gene transfer through the blood-nerve barrier: NGF-engineered neuritogenic T-lymphocytes attenuate experimental autoimmune neuritis. Nat Med 1995, 1: 1162-6.
82. Moritani, M., Yoshimoto, K., Li, S. et al. Prevention of adoptively transferred diabetes in NOD mice with IL-10-transduced islet-specific Th1 lymphocytes. J Clin Invest 1996, 98: 1851-9.
83. Gossen, M., Freundlieb, S., Bender, G., Müller, G., Hillen, W., Bujard, H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995, 268: 1766-9.
84. Mageed, R.A., Adams, G., Podhajcer, O.L., Chernajovsky, Y. Prevention of collagen-induced arthritis in mice by down regulating Th1 cells using gene delivery of soluble human p75 TNF receptor, (submitted) 1997.
85. + T-cell clones provides a co-stimulatory signal for human B-cell activation. J Exp Med 1993, 177: 1575-85.
86. Grell, M., Douni, E., Wajant, H. et al. The transmembrane form of TNF is the prime activating ligand of the 80kDa TNF receptor. Cell 1995, 83: 793-802.
87. Raz, E., Watanabe, A., Baird, S.M. et al. Systemic immunological effects of cytokine genes injected into skeletal-muscle. Proc Natl Acad Sci USA 1993, 90: 4523-7.
88. Raz, E., Dudler, J., Lotz, M., Baird, S.M., Berry, C.C., Eisenberg, R.A., Carson, D.A. Modulation of disease activity in murine lupus erythematosus by cytokine gene delivery. Lupus 1995, 4: 286-92.
89. Giladi, E., Raz, E., Karmeli, F., Okon, E., Rachmilewitz, D. TGF-β gene therapy ameliorates experimental colitis in rats. Eur J Gastroent Hepatol 1995 7: 341-7.
90. Fontana, A., Constam, D.B., Frei, K., Malipiero, U., Pfister, H.W. Modulation of the immune response by TGF-β. Int Arch Allergy Immunol 1992, 99: 1-7.
91. Günther, M., Haubeck, H.-D., Van de Leur, E. et al. TGFβ1 regulates TIMP-1 expression in differentiated articular chondrocytes. Arthritis Rheum 1994, 37: 395-405.
92. Morales, T.I., Roberts, A.B. TGF-β regulates the metabolism of proteoglycans in bovine cartilage organ cultures. J Biol Chem 1988, 263: 12828-31.
93. Arsura, M., Wu, M., Soneshein, G. TGFβ1 inhibits NF-κB/Rel activity inducing apoptosis of B-cells: Transcriptional activation of IκBα. Immunity 1996 5: 31-40.
94. Khoury, S.J., Hancock, W.W., Weiner, H.L. Oral tolerance to MBP and natural recovery from EAE are associated with downregulation of inflammatory cytokines and differential upregulation of TGF-β, IL-4 and prostaglandin E expression in the brain. J Exp Med 1992, 176: 1355-64.
95. Maier, R., Ganu, V., Lotz, M. IL-11, an inducible cytokine in human articular chondrocytes and synoviocytes, stimulates the production of the tissue inhibitor of metalloproteinases. J Biol Chem 1993, 268: 21527-32.
96. Fearon, D.T., Carter, R.H. The CD19/CR2/tapa-1 complex of B-lymphocytes: linking natural to acquired immunity. Ann Rev Immunol 1995, 13: 127-49.
97. Brigido, M.M., Polymenis, M., Stollar, B.D. Role of mouse Vh 10 and VL gene segments in the specific binding of antibody to Z-DNA, analyzed with recombinant single chain Fv molecules. J Immunol 1993, 150: 469-79.
98. Eshhar, Z., Waks, T., Gross, G., Schindler, D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding doamins and the γ or ζ subunits of the immunoglobulins and T-cell receptors. Proc Natl Acad Sci USA 1993, 90: 720-4.
99. Morgenstern, J.P., Land, H. Advanced mammalian gene transfer: High titer retroviral vectors with multipledrug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990, 18: 3587-96.